FDA is investigating whether CAR-T, a cancer therapy pioneered at Penn, can cause lymphoma

PHILADELPHIA — The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug Administration announced Tuesday an investigation into whether

Related Keywords

Philadelphia ,Pennsylvania ,United States ,University Of Pennsylvania , ,Drug Administration ,Health And Wellness ,Blood Disorders ,Dancer ,Cellular Therapy ,Edical Conditions And Diseases ,Emerging Treatments ,Leukemia And Hematological Cancer ,Medical And Pharmaceutical Regulation ,Reatments And Therapies ,Olitics And Government ,Overnment Agencies Us ,Food And Drug Administration ,Department Of Health And Human Services ,Government Regulation ,North America ,Americas ,New York ,New York City ,Medicine ,Ncology ,Iology ,Rade ,Mmunology ,He Economy ,Police ,Harmacology ,Natomy ,Hospitals ,Enetics ,Ytology ,